Table 1.
Characteristics of 24 included studies (SR-aGVHD)*.
| Studies | Median age/year (range) | HLA matching (n) | SR-aGVHD grade (n) | Median time from SR-aGVHD diagnosis to the application of ruxolitinib/day (range) | ||||||
|---|---|---|---|---|---|---|---|---|---|---|
| MRD | mMRD | MUD | mMUD | I | II | III | IV | |||
| Zeiser, 2020 | 52.5 (12–73) | NA | NA | NA | NA | 2 | 50 | 68 | 30 | NA |
| Modemann, 2020 | 58.5 (21–73) | 3 | 0 | 9 | 6 | 0 | 0 | 9 | 9 | 87 (35–257) |
| Lancman, 2018 | 58 (33–61) | NA | NA | NA | NA | 1 | 3 | NA | NA | NA |
| Assouan, 2017 | 52 (26–65) | 5 | NA | 5 | NA | NA | NA | 6 | NA | 14 |
| Wei, 2021 | 30 (11–56) | 5 | NA | NA | NA | NA | 9 | 8 | 6 | 5 (1–79) |
| Leung, 2022 | 38 (19–63) | NA | NA | NA | NA | 0 | 13 | 4 | 5 | NA |
| Moiseev, 2020 | 17 (1–67) | 2 | NA | 19 | NA | 0 | 11 | 10 | 11 | 16 (5–113) |
| Jagasia, 2020 | 58 (18–73) | 18 | 11 | 27 | 10 | 0 | 23 | 34 | 14 | NA |
| Biliński, 2021 | 53.5 (22–66) | 2 | NA | 2 | NA | NA | NA | NA | 4 | NA |
| Liu, 2021 | 29 (13–63) | NA | NA | NA | NA | 0 | 7 | 22 | 11 | NA |
| Laisne, 2020 | 4.3 (0.4–14.5) | NA | NA | NA | NA | 0 | 7 | 13 | 9 | 91 (17–518) |
| González, 2018 | 11 (5–18) | NA | NA | NA | NA | 0 | 0 | 4 | 9 | 9 |
| Maldonado, 2017 | 51 (28–56) | 1 | NA | NA | NA | NA | NA | 3 | NA | NA |
| Maldonado, 2021 | 32 (26–48) | NA | NA | NA | NA | NA | NA | 2 | 7 | NA |
| Meng, 2019 | 23.5 (8–38) | 12 | NA | NA | NA | 0 | 6 | 5 | 1 | NA |
| Mozo, 2021 | 8.6 (0.8–18.1) | 3 | NA | 3 | NA | NA | NA | 2 | 6 | NA |
| Khandelwal, 2017 | 8.5 (1.6–16.5) | 1 | NA | 12 | NA | NA | 2 | 9 | 2 | 147 (55–538) |
| Zeiser, 2015 | 51 (21–75) | 13 | NA | 15 | NA | NA | NA | NA | NA | NA |
| Abedin, 2019 | 59 (46–70) | 6 | 2 | 10 | 1 | NA | 3 | 13 | 3 | 21 (3–162) |
| Dang, 2020 | 35 (19–55) | 8 | 2 | NA | NA | NA | NA | 9 | NA | NA |
| Uygun, 2020 | NA | 4 | NA | 17 | NA | NA | 2 | 4 | 7 | 28 (7–231) |
| Gómez, 2019 | 51 (0–73) | 33 | NA | 39 | NA | NA | 3 | 20 | NA | NA |
| Toama, 2020 | 55 (27–72) | 7 | NA | 24 | NA | NA | NA | NA | NA | 17 (2–280) |
| Zhao, 2020 | 29 (14–62) | 5 | 55 | 4 | NA | NA | NA | 22 | 42 | 8 (3–89) |
HLA, human leukocyte antigen; mMRD, mismatched related donor; MRD, matched related donor; mMUD, mismatched unrelated donor; MUD, matched unrelated donor; NA, not available; SR-aGVHD, steroid-refractory acute graft-versus-host disease.*Thirteen studies included both SR-aGVHD and SR-cGVHD analysis.